| 2026-03-11 |
复牌提示：
2026-03-11 10:15:38 停牌，复牌日期 2026-03-11 10:20:38
|
| 2026-02-13 |
详情>>
股本变动：
变动后总股本1002.89万股
|
| 2026-02-13 |
详情>>
业绩披露：
2025年年报每股收益-1.79美元,归母净利润-508.73万美元,同比去年增长-37.27%
|
| 2025-08-15 |
股东大会：
将于2025-09-25召开股东大会
会议内容 ▼▲
- 1.To approve, as an ordinary resolution, the re-election of each of the seven directors named in the proxy statement as a director of the Company to hold office until the next annual general meeting, or until each successor is duly elected and qualified (the “Re-election of Director”);
2.To approve, as an ordinary resolution, the ratification of the re-appointment of AssentSure PAC as the Company’s independent registered public accounting firm for the fiscal year ended September 30, 2025 (the “Ratification of Auditor Appointment”);
3.To pass the following special resolution:
“It is resolved as a special resolution that the Company change its name in English from ‘Golden Sun Health Technology Group Limited’ to ‘Golden Sun Technology Group Limited’ and change its dual foreign name from ‘金太阳健康科技集团有限公司’ to ‘金太阳科技集团有限公司,’ with immediate effect” (the “Name Change”);
4.To pass the following special resolution: “It is resolved as a special resolution that, subject to and immediately upon the effectiveness of the Name Change, the Company adopt amended and restated memorandum and articles of association in substitution for, and to the exclusion of, the Company’s existing memorandum and articles of association, to reflect the Name Change” (the “Amended M&A Adoption with respect to Name Change”);
5.To pass the following special resolution:
“It is resolved as a special resolution that, subject to the Company receiving consent to the Class B Variation (as defined in the proxy statement) from Class A and Class B shareholders in accordance with Article 2.8 of the Company’s current articles of association, the Company adopt the amended and restated articles of association in the form annexed to the proxy statement in substitution for, and to the exclusion of, the Company’s existing articles of association, to, amongst other things, reflect the Class B Variation (as defined in the proxy statement)” (the “Amended Articles Adoption with respect to Class B Variation”);
6.To approve, as an ordinary resolution that, with immediate effect, the authorized share capital of the Company be increased from US$50,000 divided into 9,000,000 Class A ordinary shares with a par value of US$0.005 each and 1,000,000 Class B ordinary shares with a par value of US$0.005 each to US$1,000,000 divided into 180,000,000 Class ordinary shares with a par value of US$0.005 each and 20,000,000 Class B ordinary shares with a par value of US$0.005 each (the “Share Capital Increase”);
7.To pass the following special resolution:
“It is resolved as a special resolution that, subject to the Share Capital Increase being approved and effected, the Company adopt amended and restated memorandum of association in substitution for, and to the exclusion of, the Company’s existing memorandum of association, to reflect the Share Capital Increase” (the “Amended MoA Adoption with respect to Share Capital Increase”);
8.To approve, as an ordinary resolution, to adjourn the AGM (as defined in the proxy statement) to a later date or dates or sine die, if necessary, to permit further solicitation and vote of proxies if, at the time of the AGM, there are not sufficient votes for, or otherwise in connection with, the approval of the foregoing proposals or any proposal to be presented at the EGM (as defined in the proxy statement) of the holders of Class A ordinary shares of the Company (the “AGM Adjournment”).
|
| 2025-08-08 |
详情>>
业绩披露：
2025年中报每股收益-2.42美元,归母净利润-479.47万美元,同比去年增长-172.61%
|
| 2025-02-14 |
详情>>
业绩披露：
2024年年报每股收益-1.87美元,归母净利润-370.62万美元,同比去年增长35.95%
|
| 2024-09-10 |
股东大会：
将于2024-10-08召开股东大会
会议内容 ▼▲
- 1.To re-elect Mr. Xueyuan Weng as a director of the Company to hold office until the next annual general meeting.
2.To re-elect Mr. Liming Xu as a director of the Company to hold office until the next annual general meeting.
3.To re-elect Ms. Peilin Ji as a director of the Company to hold office until the next annual general meeting.
4.To re-elect Mr. Yidong Hao as a director of the Company to hold office until the next annual general meeting.
5.To re-elect Mr. Zhenghua Yu as a director of the Company to hold office until the next annual general meeting.
6.To re-elect Mr. Xiao Jin as a director of the Company to hold office until the next annual general meeting.
7.To re-elect Mr. Xijing Xu as a director of the Company to hold office until the next annual general meeting.
8.To ratify the appointment of AssentSure PAC as the Company’s independent registered public accounting firm for the fiscal year ending September 30, 2024.
9.To ratify and confirm that effective from the Company’s date of incorporation, the financial year of the Company shall end on September 30 in each year and begin on October 1 in each year.
10.To consider any other business properly presented at the Meeting.
|
| 2024-08-02 |
详情>>
业绩披露：
2024年中报每股收益-0.89美元,归母净利润-175.88万美元,同比去年增长52.13%
|
| 2024-04-17 |
详情>>
拆分方案：
每10.0000合并分成1.0000股
|
| 2024-03-21 |
股东大会：
将于2024-04-11召开股东大会
会议内容 ▼▲
- 1.To approve a share consolidation that,effective on April 18, 2024:a.the authorised, issued, and outstanding shares of the Company (collectively, the Shares) be consolidated and divided by consolidating:I.every ten (10) Class A Ordinary Shares with a par value of US$0.0005 each into one (1) Class A Ordinary Share with a par value of US$0.005 each;II.every ten (10) Class B Ordinary Shares with a par value of US$0.0005 each into one (1) Class B Ordinary Share with a par value of US$0.005 each,with such consolidated Shares having the same rights and being subject to the same restrictions (save as to par value) as the existing Shares of such class as set out in the Company’s memorandum and articles of association (the Share Consolidation);b.as a result of the Share Consolidation, the authorised share capital of the Company be amended from US$50,000 divided into 90,000,000 Class A Ordinary Shares with a par value of US$0.0005 each and 10,000,000 Class B Ordinary Shares with a par value of US$0.0005 each to US$50,000 divided into 9,000,000 Class A Ordinary Shares with a par value of US$0.005 each and 1,000,000 Class B Ordinary Shares with a par value of US$0.005 each;c.no fractional Shares be issued in connection with the Share Consolidation and, in the event that a shareholder would otherwise be entitled to receive a fractional Share upon the Share Consolidation, the total number of Shares to be received by such shareholder be rounded up to the next whole Share.
|
| 2024-02-08 |
详情>>
业绩披露：
2023年年报每股收益-0.31美元,归母净利润-578.63万美元,同比去年增长-170.47%
|
| 2023-10-12 |
详情>>
业绩披露：
2023年中报每股收益-0.2美元,归母净利润-367.43万美元,同比去年增长-1206.49%
|
| 2023-08-25 |
股东大会：
将于2023-09-26召开股东大会
会议内容 ▼▲
- 1.To re-elect Mr. Xueyuan Weng as a director of the Company to hold office until the next annual general meeting.
2.To re-elect Ms. Peilin Ji as a director of the Company to hold office until the next annual general meeting.
3.To re-elect Mr. Liming Xu as a director of the Company to hold office until the next annual general meeting.
4.To re-elect Mr. Robert Travers as a director of the Company to hold office until the next annual general meeting.
5.To re-elect Mr. Wenlong Xia as a director of the Company to hold office until the next annual general meeting.
6.To re-elect Mr. Yidong Hao as a director of the Company to hold office until the next annual general meeting.
7.To elect Mr. Zhenghua Yu as a director of the Company to hold office until the next annual general meeting.
8.To change the Company’s name to “Golden Sun Health Technology Group Limited” and the Chinese translation of the Company’s name to “金太阳健康科技集团有限公司”.
9.To adopt a third amended and restated memorandum and articles of association in the form set out in Annex A to the accompanying proxy statement in substitution for, and to the exclusion of, the current amended and restated memorandum and articles of association of the Company.
|
| 2023-02-15 |
详情>>
业绩披露：
2022年年报每股收益-0.15美元,归母净利润-213.93万美元,同比去年增长-208.13%
|
| 2022-08-16 |
详情>>
业绩披露：
2022年中报每股收益0.03美元,归母净利润33.21万美元,同比去年增长-77.23%
|
| 2022-02-11 |
详情>>
业绩披露：
2021年年报每股收益0.16美元,归母净利润197.86万美元,同比去年增长4609.61%
|
| 2022-02-11 |
详情>>
业绩披露：
2020年年报每股收益0.01美元,归母净利润4.20万美元,同比去年增长-98.75%
|
| 2021-09-06 |
温馨提示：
美股因劳工节，9月6日休市一天
|